1 Lees AJ, Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with ealry, mild Parkinson's disease, British Medical Journal 311:1602-1607, December 1995.
2 Sweet RD, McDowell FH, Five years' treatment of Parkinson's disease with levadopa, Annals Intern Med., 83:456-463, 1975.
3 Hornykiewicz O, Brain transmitter changes in Parkinson's disease, in Movement Disorders, eds CD Marsden and Fahn, Butterworth & Co., London, p41, 1982
4 Knoll J, the striatal dopamine dependency of life span in male rats. Longevity study with (-) deprenyl, Mech. Ageing Dev, 46:237-262, 1988.
5 Knoll J, Dallo J, Yen TT, Striatal dopamine, sexual activity and lifespan. Longevity of rats treated with (-)deprenyl. Life Sci. 45:525-531, 1989.
6 Coehn G, Pasik P, Cohen B, et al. Pargyline and deprenyl prevent the neurotoxicity of l-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys, Eur J Pharmacol, 106:209, 1984.
7 Knoll J, Dallo J, Yen TT, Striatal dopamine, sexual activity and lifespan. Longevity of rats treated with (-)deprenyl. Life Sci. 45:525-531, 1989.
8 Brikmayer W, Knoll J, Riederer P,et al. Increased life expectancy resulting from addition of L-deprenyl to madopar treatment in parkinson's disease: A long termstudy, J Neural Transm, 64:119-127, 1985.
9Parkinson Study Group, Effect of deprenyl on the progression of disability in early Parkinson's disease, New Engl J Med, 321:1364-1371, 1989.
10 Elsworth JD, Glover V, Reynolds GP, et al Deprenyl administration in man: selective monoamiline oxidase B inhibitor without the "cheese effect", Psychopharmacology, 57:33-38, 1978.
11 Robinson DS, Changes in monoamine oxidase with human development and aging, Fed Proc, 34:103-107, 1975.
12 Tipton KF, What is it that L-deprenyl (selegiline) might do? Clin Pharmacol Ther, 56:781-796, 1994.
13 Tatton WG and greenwood CE, rescue of dying neurons: a new actionfor deprenyl in MTPT Parkinsonism, J Neurosci Res, 30:P666-672, 1991.
14 Salo PT and tatton Wg, Deprenyl reduces the death of motoneurons caused by axotomy, J Neurosci Res, 31:394-400.
15 Tatton WG, Ansari K, Ju W, et al. Selegiline Induces "Trophic-Like" Rescue Of Dying Neurons Without MAO Inhibition, Neurochemistry in Clinical applications, eds. Tang L and Ynag S,. p. 15-16, Plenum Press, NY 1995.
16 Olanow CW, the early treatment of parkinson's disease, Neurology, 43 (suppl): S1-30-S1-31, 1993.
17 Mangoni A, Grassi MP, Frattola L, et al. Effects of a MAO-B inhibitor in the treatment of Alzheimer disease, Eur Neurol, 31: 100-107, 1991
18 Maki-Ikola; O,Kilkku O, Heinonen, E, Other studies have not shown increased maortality (letter), British Medical Journal, 312:702, March 1996.
19 Maki-Ikola; O,Kilkku O, Heinonen, E, Other studies have not shown increased maortality (letter), British Medical Journal, 312:702, March 1996.
20 Parkinson Study Group, Impact of Deprenyl and Tocopherol Treatment on Parkinson's Disease in DATATOP subjects not patients Requiring Levadopa, Annals of Neurology, 39:1:37-43, January 1996.
21 Parkinson Study Group, Impact of Deprenyl and Tocopherol Treatment on Parkinson's Disease in DATATOP subjects patients Requiring Levadopa, Annals of Neurology, 39:1:37-43, January 1996.
22 Anderson KB, Girdwood AG, WilsonJa, Stopping selegiline may lead to problems for patients (letter), British Medical Joiurnal 312:702, 16 March 1996.
23 Wu,R-M, Chuich CC, Pert A, et al. Apparent antioxidant effect of i-deprenyl on hydroxyl radical formation and nigral formation and nigral injury elicited by MPP+ in vivo, Eur J of Pharmacol, 243:241-247, 1993.
24 Walkinshaw G and Waters CM, Neurotoxin-induced cell death in neuronal PC12 cells is mediated by induction of apoptosis, neuroscience, 63:4:975-987, December 1994.
25 Zhang X and Yu PH, Depletion of Nos Activty in the rat Dentate Gyrus neurons by DSP-4 and protection by Deprenyl, Brain Research Bulletin, 38:4:307-311, 1995.
26 Zeng TC, BongraninS, Bronzetti E, et al. Influence of longterm treatment with L-deprenyl on the age-dependent changes in rat brain micrpanatomy, Mech Ageing Dev, 73:2:113-126, February 1994.
27 Carrillo MC, Kanai S, Nokubo M, et al. (-) Deprenyl induces activities of both superoxide dismutase and catalse but no og glutathanione peroxidae in the striatum of young rats, Life Sci, 48:517 521,1991
28 Carrillo MC, Kanai S, Nokubo M, et al. The ability of (-) deprenyl to increase suoperoxide dismutase activities in the rats ids tissue and brain region selective, Life Sci, 50:1985-1992, 1992
29 Rinne JO, Roytta M, Paljarvi L, et al. Selegiline (deprenyl) treatment and death of nigral neurons in Parkinson's disease, Neurology, 41:859-861,June 1991.
30 Gelowitz, DL Richardson JS, Wishart TB, et al. Chronic L-deprenyl or L-Amphetamine: Equal Cognitive Enhancement, Unequal MAO Inhibition, Pharmacology Biochemistry and behavior, 47:41-45, 1994
31 Head E, Hartley J, Kameka AM, et al. The effects of L-deprenyl on spatial, short term memory in memory in young and ages dogs, Progress in Neuropsychopharmacology & Biological Psychiatry, 20 : 3:515-530, April 1996
32 Knoll J, Deprenyl (selegiline): the history of its development and pharmacologiacl action. Acta Neurol Scand, 68 (Suppl 95) : 57-80, 1993
33 Elizan TS, Yahr MD, Moros DA, et al Selegiline use to prevent progression of Parkinson's disease, Arch neurol, 46:1275-1279, 1989.
34 Shaw KM, Lees AJ, Stern GM, The impact of treatment with levadopa on Parkinson's disease, Quar J Med 195:283-293 1980.
35 Chiueh CC, Wu RM, Mohanakumar KP, et al. In vivo generation of hydroxyl radicals and MPTP-induced dopaminergic toxicity in the the basal ganglia, Ann NY Acad.Sci, 738:25-36, Nov 17, 1994
36 Michel PP, Hefti F, Toxicity of 6-hydroxydopamine and dopamine for dopaminergic neurons in culture, J Neurosci Res, 26:4:428-33, August 1990. \
37 Halliwell B, Reactive oxygen species and the central nervous system, J Neurochem, 59:1609-1614,1991.
38 Dorit B-S, Riederer P, YoudimMBH, Iron-Melanin Interaction and Lipid Peroxidation: Implications for Parkinson's disease, J Neurochem, 57:5:1609-1614, 1991.
39 Gerlach M, Riederer P, Youdim, MBH, Neuroprotective Therapeutic Strategies: Comparison of Experimental and Clincal Results, Biochem Pharmacol, 50:1:1-16, 1993.
40 Zigmond MJ, Hastings TG, Abercrombie ED, Neurochemical responses to 6-hydrodopamine and L-Dopatherapy: implications for Parkinson's Disease, 648:71-86, May 11, 1992.
41 Pardo B, Mena MA, Casarejos MJ, et al. Toxic effects of L-Dopa on mesencephalic cell cultures: protection with antioxidants, Brain Res, 682:1-2:133-143, June 5, 1995.
42 Walkinshaw G and Waters CM, inductionof apoptosis in catecholaminergic PC12 cells by L-DOPA: Implications for the treatment of Parkinson's Disease.
43 Smith TS, Parker WD Jr, Bennnett JP jr, L-Dopa increases nigral production of hydroxyl radical in vivo: potential L-Dopa toxicty?, Neuroreport, 5:8:1009-1011, April 14,1994.
44 Mytilineou C, Han Sk, Cohen G, Toxic and protective effects of L-Dopa on mesencephalic cell cultures, J Neurochem, 61:4:1470-1478, October 1993.
45 Excitology of L-dopa and 6-OH-dopa: implications for Parkinson's disease and Huntington's disease, Exp Neur, 108:3:269-272, June 1990.
46 Wilson DF, Factors affecting the rate and energetics of mtiochondrial oxidative phosphorylatiobn, Med Sci Sports Exer, 26:1:37-43.
47 Cooper JM, Daniel SE, Marsden CD, et al. L-Dihydroxyphenylalanine and complex I deficiency in Parkinson's disease brain Mov Disord, 10:3:295-297, May 1995.
48 Birkmayer JG, Vrecko C, Vole D, et al. Nicotinamide adenine dinucleotide (NADH)- a new therapeutic approach to Parkinson's disease, a comparison of oral and parenterl application, Acta Neurol Scnad Suppl, 146: 32-35, 1993
49 Life Extension magazine, p.23-31 , June 1996.
50 Lindsay RM, Altar CA, Cedar baum JM et al. The therapeutic Ptential of Neurotrophic Factors in the Treatment of Parkinson's disease, Exp Neurol, 124:103-11, 1993